484 studies on Insulin curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study provides compelling evidence that GPER activation with a selective agonist like G-1 can effectively ameliorate key features of obesity and type 2 diabetes in preclinical models. The ability of G-1 to reduce…
This large-scale registry is crucial for understanding the current state of obesity and Type 2 Diabetes Mellitus management in China, a region with unique dietary and lifestyle factors. The real-world data collected w…
The development of highly effective weight loss medications is crucial for addressing the global obesity epidemic, which contributes to numerous health complications. While individual GIP RAs and amylin agonists show …
While this specific study did not yield data, the initial intent highlights a critical area of need: understanding how combination therapies like IDegLira perform in real-world settings for patients whose Type 2 Diabe…
The abstract outlines the study's primary objective to determine the effectiveness and safety of adding GLP-1 agonist therapy to basal insulin. The investigators hypothesized that this combination would lead to statis…
This Phase 3 trial is crucial for optimizing Type 2 Diabetes management by evaluating a potentially simpler, yet effective, treatment option. If IDegLira demonstrates comparable efficacy and a favorable safety profile…
This study provides strong evidence supporting the enhanced efficacy of combining a basal insulin (insulin degludec) with a GLP-1 receptor agonist (liraglutide, a class of drugs that mimic a natural hormone to lower b…
The key implication of this research is the potential for IDegLira to offer a significantly safer and more effective therapeutic option for Type 2 Diabetes patients transitioning from hospital to home. By reducing the…
As this PHASE 4 clinical trial is currently RECRUITING participants, specific findings are not yet available, with an estimated completion date of 2026-07-01. Researchers are meticulously collecting data from an estim…
This research provides crucial insights into the physiological fluctuations of kisspeptin and irisin during the normal menstrual cycle, highlighting their potential roles beyond their previously established functions.…
This study highlights Kisspeptin-10 as a promising novel therapeutic candidate for the management of obesity and type 2 diabetes. Its multifaceted action, involving both the enhancement of beneficial gut hormones and …
The successful completion of this Phase 3 trial is a significant milestone, as Tirzepatide (a dual GIP and GLP-1 receptor agonist) has already demonstrated robust efficacy in adults with Type 2 Diabetes and obesity. I…
This meta-analysis provides robust evidence that serum kisspeptin levels are consistently lower in women with PCOS, suggesting its potential as a novel biomarker for the condition. The findings deepen our understandin…
This research provides novel and critical mechanistic insights into how IGFBP-3 modulates cellular responses to growth factors, unequivocally identifying sphingosine kinase as a pivotal downstream effector in this pro…
This research provides compelling evidence that recombinant IGF-1 can induce targeted organ growth, rather than generalized, uncontrolled proliferation, in a developing fetus. This specificity is critical, as it sugge…
This research provides compelling evidence that GH and IGF-I can effectively counteract the decline in milk production during prolonged lactation, suggesting new avenues for intervention. The distinct yet complementar…
This research provides critical insights into the intricate mechanisms governing coordinated cardiac and vascular development, particularly during vulnerable fetal stages. Understanding how IGF-1 orchestrates this bal…
This research provides compelling evidence that sustained elevated IGF-1 during fetal development directly programs pancreatic beta-cell dysfunction, leading to reduced glucose-stimulated insulin secretion. This is a …
This research highlights the fundamental importance of N-linked glycosylation for optimal IGF-1 signaling, providing crucial insights into cell biology and receptor function. Given that CHO cells are the primary indus…
This research highlights a complex interplay between IGF-1 and fetal glucose metabolism, suggesting that the in vivo effects of IGF-1 LR3 on insulin secretion are not solely due to direct actions on pancreatic beta ce…
This research highlights a critical insight into Alzheimer's disease pathology, suggesting that interventions solely focused on modifying amyloid plaques may not always translate into tangible cognitive benefits. The …
This study suggests that IGF-1 LR3 may not be an effective therapeutic strategy for reversing late-gestation intrauterine growth restriction (IUGR), even when systemic levels of IGF-1 are significantly elevated. The f…
This research highlights a highly promising therapeutic strategy for treating volumetric muscle loss, a condition with limited effective treatments. By demonstrating that localized and sustained delivery of IGF-1 via …
This research highlights a promising therapeutic avenue for obesity and related metabolic disorders by leveraging the body's own growth hormone system. Activating the GHSR could offer a strategy to improve body compos…
This research is critical for understanding the molecular mechanisms behind skin aging and its response to environmental stressors like UVB. If Insulin-Like Growth Factor 1 proves effective in modulating gene expressi…
This study highlights the potential of Mazdutide as a highly effective treatment option for type 2 diabetes, particularly in the Chinese adult population, addressing both glycemic control and significant weight manage…
This comprehensive evaluation provides critical evidence supporting the superior efficacy of certain long-acting GLP-1 RAs in managing Type 2 Diabetes, particularly concerning glycemic control and weight reduction. Th…
The exploration of ARA 290, a non-hematopoietic erythropoietin analogue, holds significant promise as it targets a novel mechanism for glucose regulation, potentially offering a new therapeutic avenue beyond existing …
This research establishes selective amylin receptor agonism as a powerful new therapeutic strategy for metabolic diseases, potentially offering superior benefits over existing incretin-based therapies. The distinct me…
This blueprint provides a standardized, multi-faceted approach to evaluating the long-term efficacy of novel anti-obesity treatments like survodutide, moving beyond simple weight loss metrics. By focusing on disease m…
This review underscores the significant therapeutic potential of survodutide as a novel treatment for both obesity and MASH, leveraging its unique dual GLP-1 and glucagon receptor agonism. Its ability to induce substa…
While this specific study did not yield results, the initial intent highlights the potential scientific interest in Kisspeptin-10 as a modulator of insulin secretion. If future research successfully demonstrates a rol…
Understanding the interplay between reproductive hormones like kisspeptin and metabolic processes could open new avenues for treating metabolic diseases. If kisspeptin were found to positively influence insulin secret…
Understanding the specific receptor binding profiles of BI 456906 is a critical first step in evaluating its potential as a novel therapeutic agent for obesity. If BI 456906 demonstrates significant and distinct gluca…
This comprehensive review underscores the immense potential of novel drug targets, innovative drug classes, and cutting-edge technologies to revolutionize the treatment landscape for metabolic diseases. The insights g…
This summary highlights the continued global scientific focus on obesity as a multifaceted disease with profound implications for public health. The emphasis on novel therapeutic approaches presented at the WCIRDC sug…
The development of multi-agonist incretin therapies and novel non-incretin pathways represents a critical advancement, offering more potent and comprehensive treatment options for obesity and Type 2 Diabetes than ever…
This study highlights Dapagliflozin's potential as a valuable adjunctive therapy for Type 1 Diabetes patients struggling with optimal glycemic control despite existing Insulin and Liraglutide regimens. The observed be…
This pilot study represents a novel approach to Type 2 Diabetes Mellitus management, focusing on an intensive, short-term intervention to potentially reverse or significantly improve disease progression. If successful…
This comprehensive review is crucial for raising awareness among clinicians about the high burden of MASLD in PLWH and its potential for severe liver outcomes. By consolidating current knowledge, it provides a valuabl…
These hypothetical findings suggest that GLP-1 receptor agonists like Liraglutide or GIK infusions could offer safer and more effective perioperative glycemic control for patients with Type II Diabetes Mellitus underg…
The preservation of lean body mass during weight loss is a critical factor for long-term health, metabolic function, and sustained weight management. This study's findings demonstrate that MyoPreserve offers a novel p…
Understanding the real-world effectiveness of combination therapies like Xultophy® is crucial for optimizing Type 2 Diabetes management. This study provides valuable data on how a fixed-ratio combination of insulin de…
Treatment with Cagrilintide resulted in profound and statistically significant reductions in body weight and substantial improvements across multiple metabolic markers. > The high-dose Cagrilintide group exhibited a r…